EfficacyofS-1vscapecitabineforthetreatmentofgastriccancer:Ameta-analysis

摘要： AIM:TorationallyevaluatetheeffectofS-1vscapecitabineforthetreatmentofgastriccancer.METHODS:MEDLINE,EMBASE,CochraneControlledTrialsRegister,GoogleScholar,andChinaJournalFullTextDatabasewereaccessedtocollectclinicalrandomizedcontrolledtrialsregardingtheeffectofS-1vscapecitabineforthetreatmentofgastriccancerpatients.Statisticalanalysiswasperformedbymetaanalysis.Fourrandomizedcontrolledtrialsmettheinclusioncriteria.RESULTS:Comparedwithcapecitabineregimens,the1-yearsurvivalrateingastriccancerpatientswas0.80(95%CI:0.52-1.21,P=0.29).TheoverallresponserateofS-1vscapecitabinewas0.94(95%CI:0.59-1.51,P=0.93).Comparedwithcapecitabineregimens,themostfrequenthematologictoxicitieswereneutropenia(OR=0.99,95%CI:0.65-1.49,P=0.94)andthrombocytopenia(OR=0.72,95%CI:0.31-1.67,P=0.44).Themostfrequentnon-hematologictoxicitiesincludednausea(OR=0.85,95%CI:0.56-1.28,P=0.43)andhand-footsyndrome(OR=0.16,95%CI:0.10-0.27,P<0.00001).CONCLUSION:TheexistingstudiessuggestthatS-1isnotmoreeffectivethancapecitabineinthetreatmentofgastriccancerpatients,butdoesexhibitlesstoxicitywithregardtohand-footsyndrome. ... （共7頁）